Dear members of the ESC Working Group on Cardiovascular Pharmacotherapy,
I am pleased to take over this vibrant working group and thank the previous chairman Prof. Heinz Drexel for his excellent leadership during the last years. Please find below information about some of our numerous activities. I hope you enjoy one of these activities and I cordially invite you to actively participate in one of our activities.
Regarding educational activities we have been forced by the COVID-19 pandemic to change the formats of our courses on "All About Clinical Courses" (10. and 11. December 2020) as well as on "Pharmacotherapy in Old People" (25. and 26. November 2020) to online webinars. This transition has many advantages for you to participate. On our webpage you will find the preliminary programmes. In the near future, this will be our favorite format. I will highlight that the "Pharmacotherapy in Old People" is in collaboration with the Karolinska Institute, Stockholm, Sweden, where there is a PhD course.
Clarivate has released the 2019 Impact Factor scores. The European Heart Journal – Cardiovascular Pharmacotherapy received a score of 6.7, which ranks the journal number 16 in the world in the Cardiac & CV Systems category. The journal remains the number one journal dedicated to cardiovascular pharmacology in the world. We are very grateful to all of our authors, reviewers, editors, and the EHJ-CVP family. Thank you!
In the September issue of the journal, we introduce a new section entitled ‘Pharmapulse’ which will report on interesting events and people within the cardiovascular pharmacology world.
The updated version of the ESC Handbook on Cardiovascular Pharmacotherapy came live online July 2020. Moreover, the online version is presently being updated with the 2020 ESC Guidelines on NSTEMI and Atrial Fibrillation. It will probably come live around end 2020.
On behalf of the Working Group nucleus,
Alexander Niessner, Chairperson 2020-2022
Our mission: To reduce the burden of cardiovascular disease.